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Abstract: 
Cystic fibrosis (CF), caused by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene, is the most common 
inherited life-limiting disease in North European people affecting 90,000 
people worldwide. Progressive lung damage caused by recurrent infection 
and chronic airway inflammation is the major determinant of survival with 
a median age at death of 29 years. Approximately 60% of CF patients are 
infected with Aspergillus fumigatus, a ubiquitous environmental fungus, 
and its presence has been associated with accelerated lung function 
decline. Half of the patients infected with Aspergillus are <18 years of age. 
Yet, time of acquisition of this fungus and determinants of CF-related 
Aspergillus disease severity and progression are not known.  
CFTR expression has been demonstrated in cells of the innate and adaptive 
immune system and has shown to be critical for normal function. Research 
delineating the role of CFTR-deficient phagocytes in Aspergillus persistence 
and infection in the CF lung, has only recently received attention. In this 
concise review we aim to present the current understanding with respect to 
when people with CF acquire infection with A. fumigatus and antifungal 
immune responses by CF immune cells.  
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Abstract  
Cystic fibrosis (CF), caused by mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene, is the most common inherited life-limiting disease in North European 
people affecting 90,000 people worldwide. Progressive lung damage caused by recurrent 
infection and chronic airway inflammation is the major determinant of survival with a 
median age at death of 29 years. Approximately 60% of CF patients are infected with 
Aspergillus fumigatus, a ubiquitous environmental fungus, and its presence has been 
associated with accelerated lung function decline. Half of the patients infected with 
Aspergillus are <18 years of age. Yet, time of acquisition of this fungus and determinants of 
CF-related Aspergillus disease severity and progression are not known. 
CFTR expression has been demonstrated in cells of the innate and adaptive immune system 
and has shown to be critical for normal function. Research delineating the role of CFTR-
deficient phagocytes in Aspergillus persistence and infection in the CF lung, has only 
recently received attention. In this concise review we aim to present the current 
understanding with respect to when people with CF acquire infection with A. fumigatus and 
antifungal immune responses by CF immune cells. 
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Introduction  
In cystic fibrosis (CF), 90% of morbidity and mortality is a consequence of chronic 
suppurative lung disease.
1
 Aggressive targeted and chronic treatment of airway infection is 
the mainstay of clinical management, reducing lung function decline and improving 
survival.
2
 The introduction of CFTR modulators into clinical practice reduces (but does not 
abolish) pulmonary exacerbations and rate of lung function decline, and will not reverse 
existing lung damage (bronchiectasis). Even with new treatment modalities targeting CFTR 
dysfunction, pulmonary infections will continue to remain the major prognostic problem in 
CF. Research and treatment has conventionally focussed on the role of bacterial pathogens 
with little attention being paid to the role of fungal species.  
Aspergillus fumigatus is a ubiquitous fungus: inhalation of Aspergillus spores and their 
airway deposition is fact of everyday life. Susceptibility to Aspergillus-related lung disease in 
3
CF is reflected by clinical phenotypes ranging from persistent Aspergillus infection and 
bronchitis to allergic and airway invasive aspergillosis.
4
 About 60% of CF patients are 
infected with A. fumigatus and this has been associated with accelerated lung function 
decline.5-8 Little attention has been paid to the role of A. fumigatus in the pathogenesis of 
non-ABPA (allergic bronchopulmonary aspergillosis) Aspergillus lung disease in CF, despite 
its’ frequent recovery in respiratory samples. 
In vitro studies have demonstrated that CF phagocytes display reduced killing activity 
against typical CF bacterial pathogens such as Pseudomonas aeruginosa and Burkholderia 
cepacia.
9-11
 Others have reported defects in a number of host immune mechanisms 
including the release of antimicrobial peptides, intracellular alkalization, diminished 
production of hypochlorous acid, and increased release of pro-inflammatory cytokines.
12-14
 
Only a few studies can be found in the literature addressing innate antifungal immune 
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responses by CFTR-defective phagocytes and epithelial cells against A. fumigatus.
15-17
 In 
addition, 2 studies have addressed the persistent inflammation evoked by A. fumigatus 
(non-allergic) infection in an experimental CF murine model. 
18,19
 
This concise review summarizes our current understanding addressing the highly relevant 
questions of when people with CF acquire infection with A. fumigatus and why the absence 
of a functional CFTR protein in immune cells renders them susceptible to develop 
Aspergillus airway disease. 
 
Aspergillus colonisation 
The isolation of Aspergillus species, in particular A. fumigatus, in respiratory secretions of 
patients with CF is a common occurrence.
20,21
 Aspergillus fumigatus is a ubiquitous fungus 
and its conidia are dispersed in the air we breathe. In patients with CF, the impaired 
mucociliary clearance and airways being filled with thick mucus, the inhaled Aspergillus 
conidia are easily trapped. Numerous studies have reported a high variety in prevalence 
rates (ranging from 3.2% to 56.7%) and this most likely reflects the differences in culture 
techniques, the frequency of sampling, the interpretation of the culture results and if fungal 
cultures are performed as routine practice in clinical management. Authors have aimed to 
differentiate between transient colonisation (≤ 1/yr) and persistent or chronic (≥2/0.5-1yr) 
colonisation, although no consensus exists for those definitions, and some studies have 
used even stricter definitions. Table 1 provides an overview of studies in which either results 
of fungal cultures were reported as a secondary outcome or in which fungal colonisation 
was the primary focus of the study.
6,22-57
 Colonisation with Aspergillus species may be an 
apparently isolated finding, but may also be seen in the context of fungal sensitization, 
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ABPA or Aspergillus bronchitis. The majority of the studies summarized in table 1 lack 
information on this important aspect, and make it difficult to assess Aspergillus colonisation 
on its own as being harmful in terms of CF lung disease progression. To address this issue, a 
novel diagnostic classification system of Aspergillus infection and disease has been proposed 
and was consequently used to provide estimates on the prevalence of the different 
phenotypes of aspergillosis in CF using national and international CF registry data.
7,58
 As this 
novel classification system was tested in a cohort of adult patients, it remains to be seen if 
these frequencies can be used on the total CF population as almost 50% of CF patients are ≤ 
18 yrs of age. The estimated prevalences reported did not include patients colonized with 
Aspergillus in the absence of fungal sensitisation, ABPA or Aspergillus bronchitis. 
Galactomannan and Aspergillus PCR on sputum samples have been proposed to improve 
the detection of A. fumigatus and Aspergillus disease in CF.
58
 Unfortunately, no definition 
was proposed how those 2 markers should be included to define persistent colonisation. 
Most colonisation studies have focussed on A. fumigatus 
23-25,27,28,33-36,38,39,42,43,45-49,51-55,57
, 
being the most prevalent Aspergillus species encounters in human colonisation and disease, 
while others have reported Aspergillus colonisation without defining the actual 
species
6,22,26,29,30,32,37,40,41,50,56,59
. Studies reporting on the relative number of A. fumigatus 
versus non-fumigatus Aspergillus species have shown that between 36% and 58% of 
Aspergillus colonisation in patients with CF is caused by A. fumigatus.
38,40-42,46
 Jubin et al 
showed that mixed Aspergillus species colonisation may occur in up to 33% of the 
patients.
41
 
Although Aspergillus infection and disease in CF is considered to become a problem during 
adolescence and adulthood, epidemiological studies about when patients with CF acquire 
Aspergillus colonisation are scarce. Epidemiological studies conducted in France, Australia 
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and in Greece, reported a mean age of the patients at date of first isolation of A. fumigatus 
to be 12.9 yrs, 9 yrs and 13 yrs, respectively.
33,36,49
 Two more recent studies, reported an 
age of acquisition being 16.4 yrs (median, range 12.2-22.0 yrs) in the US
56
, 13.5 yrs (mean, 
SD +/- 4yrs) in France
57
, and 9.0 yrs (median, range 3.1-16.2 yrs) in the UK
51
. Two other 
studies have broken down the prevalence of A. fumigatus colonisation into different age 
categories showing colonisation rates of 16.4% up to 28% in children < 12 yrs of age.
39,43
 By 
differentiating transient (≤ 1/yr) from persistent (≥2/yr) colonisation, Saunders et al showed 
that children < 12 yrs of age were only transiently colonized in a minority of the cases (21%), 
with the majority of children ≥ 12 yrs (59%) being persistently colonised with Aspergillus.
51
 
Cultures from BAL-fluid showed a significantly higher yield of A. fumigatus compared to 
sputum samples taken in the same period.
51
 Valuable data were obtained from an 
Australian study in which infants, diagnosed with CF after newborn screening, underwent 
bronchoalveolar lavage (BAL) at the age of 3 mo, 1 yr and 2 yrs.
6
 Aspergillus was cultured 
from BAL-fluid of 7 out of 56 infants (12.5%).
6
 The difficulties in obtaining sputum samples 
from infants and young children (< 8 yrs) most likely leads to an underestimation of the 
prevalence of Aspergillus colonisation and infection in this age group, and precludes any 
conclusion about when patients with CF acquire Aspergillus infection.  
 
Aspergillus colonisation and lung disease 
Several studies have investigated the role of Aspergillus colonisation on lung function in CF 
with conflicting results. Several studies have reported either more pulmonary exacerbations 
requiring hospitalizations and/or significant lower lung function parameters and/or a 
steeper lung function decline in Aspergillus colonized patients.
5,42,45,55
 However, other 
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studies do not support an independent effect of Aspergillus colonisation on lung 
function.
29,32,37,41,43,54,56
 
McMahon showed that Aspergillus colonisation, defined as at least two sputum cultures 
positive for Aspergillus spp. at least four weeks apart in the year prior to study inclusion, 
resulted in more severe and significant bronchiectasis scored on HRCT-chest.
60
 
Noni et al showed that paediatric patients (n=121, mean age 14 yrs) with chronic Aspergillus 
colonisation (≥2 positive sputum cultures/yr) had a lower FEV1 at baseline and a faster 
deterioration of their lung function in the 7 yrs after baseline.
49
 In a large retrospective 
study using registry data from over 16,000 CF patients, lower FEV1 percent predicted was 
not a predictor of development of persistent Aspergillus colonisation.
56
  
In a systematic review by Harun et al 
61
, which included studies describing lung function 
progression over age in CF patients, only 2 out of 39 publications (between 1990-2015) 
recognized Aspergillus colonisation or disease as a possible risk factor influencing lung 
function decline.
5,62
 This reflects that Aspergillus infection and disease has not been 
recognized as playing a major role in the lung function decline in patients with CF, resulting 
in the absence of systematic approaches to monitor Aspergillus infections and disease 
longitudinally in CF patients from an early age onwards. A recent survey among paediatric 
and adult CF consultants in the UK showed that one third of the respondents considered 
Aspergillus colonisation to be potentially harmful and would therefore treat this condition.
63
   
 
Innate fungal immunity 
CFTR-defective epithelial cells  
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Direct experimental evidence of the interaction between CF epithelial cells and Aspergillus 
conidia is limited. However, there is evidence for the contribution of healthy epithelial cells 
to the innate immune response to A. fumigatus and for impairments in epithelial cell 
function in CF, from which insights can be gained. CFTR protein is highly expressed in lung 
epithelial cells and its loss leads to reduced airway surface hydration and impaired 
mucociliary transport.
64
 This is significant as Aspergillus conidia are regularly inhaled into 
the airways and the mucociliary escalator is a key mechanism for preventing colonisation. 
Pentraxin 3 is a soluble pattern recognition receptor that is secreted b epithelial cells in 
response to A. fumigatus 
65
 and is important for Aspergillus clearance.
66
 Pentraxin 3 levels 
have been found to be reduced in sputum from CF patients.
67
 
Although not the primary phagocytes of the airway, epithelial cells have been shown in-vitro 
to phagocytose conidia.
68
 Adhesion and internalisation of conidia has been shown to be 
impaired in CF bronchial epithelial cells.
15
 In the same paper authors also demonstrated 
increased baseline and Aspergillus-induced apoptosis, reduced chemokine secretion and 
impaired killing by CF epithelial cells in-vitro. In an in-vivo murine model, they found 
impaired clearance of Aspergillus conidia and evidence of epithelial necrosis and fibrin 
deposition in CFTR-deficient but not wild-type mouse airways.  Ceramide has been shown to 
accumulate in CF bronchial and alveolar epithelial cells in mice and humans.
69
 In A. 
fumigatus infection, ceramide mediates inflammation and interferes with epithelial killing of 
the fungus. Inhibition of de-novo ceramide synthesis reduced inflammatory cytokine 
release, granulocyte infiltration and fungal colonisation in a murine model of A. fumigatus 
infection.
16
  
 
CFTR-defective neutrophils  
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Human neutrophils express the CFTR protein in phagosomes and in the membranes of 
secretory vesicles and has shown to play a critical role in regulating antimicrobial neutrophil 
activities.
70-72
 Upregulating of Toll-like receptor (TLR) 5 on human CF airway neutrophils 
have been described and its signalling results in excessive cytokine production after 
stimulation with P. aeruginosa.
73,74
 A small number of functional studies implicate that the 
absence of a functional CFTR-protein in phagocytes leads to inadequate intraphagosomal 
chloride transport and less production of hypochlorous acid (HOCl) resulting in a diminished 
killing of P. aeruginosa.
9
 A study by Pohl et al. showed that impaired CFTR function in 
neutrophils leads to decreased release of secondary and tertiary granules due to altered ion 
homeostasis that is corrected by CFTR potentiator therapy.
75
 
We have recently shown that although human CF neutrophils are capable of efficiently 
phagocytose and kill A. fumigatus, this is at a cost of excessive reactive oxygen species 
(ROS).
17
 Previous studies investigating neutrophil ROS production in vitro have shown 
contrasting results, with ROS production being either increased, decreased or normal in CF 
neutrophils.
76-78
 A possible reason for this inconsistency is that this response is stimulus 
specific as a range of microbial and non-microbial stimuli were used in these studies. The 
excessive amount of ROS induced by A. fumigatus in CF neutrophils is significantly 
correlated to disease severity in terms of clinical exacerbations and lung function [Brunel 
2018].
17
 Our data suggest that the hyper inflammatory response by CF neutrophils upon 
exposure to A. fumigatus is likely to contribute to progressive lung disease.
17
 Increased 
NLRP3 expression in murine cftr-/- neutrophils was demonstrated, while pNLRC4 expression 
was inherently lower.
19
 These combined defects were shown to result in increased 
neutrophil recruitment and IL-1β release during Aspergillus infection in CF mice.
19
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CFTR-defective macrophages  
Alveolar macrophages play a key role in controlling pulmonary fungal infections both 
through direct killing of phagocytosed pathogens and by regulating the inflammatory 
response generated by inhaled fungal pathogens.
79
 There is evidence from work with 
bacteria that macrophage antimicrobial functions are impaired in CF but there is little 
experimental data looking at macrophage interactions with fungi in CF. 
CFTR expression has been demonstrated in human monocyte-derived macrophages 
11
 and 
murine and human alveolar macrophages
80,81
. These authors have reported impaired 
macrophage killing of P. aeruginosa and have proposed impaired phagosomal acidification 
as the mechanism underlying this defect. However, others have challenged this 
hypothesis.
82
 Impaired autophagy has also been reported in CF macrophages and may 
contribute to the killing defect towards B. cenocepacia as observed in one study.
10
 A similar 
autophagy defect has been reported in lung macrophages isolated from A. fumigatus 
infected CFTR-deficient mice.
19
 Recently, correction of an anti-Pseudomonal killing defect by 
treatment of CF macrophages with the CFTR corrector Lumacaftor (VX-809) was reported.
83
 
Alveolar macrophages are the primary phagocytes of the airway. Failure to kill 
phagocytosed conidia will result in germination and fungal escape out of the cell. The hyphal 
form of Aspergillus releases proteases and gliotoxins, causing further damage to the host 
airway.  
As well as failing to kill pathogens effectively, CF macrophages have also been observed to 
generate hyper-inflammatory responses to infectious stimuli. B. cenocepacia induced 
greater inflammatory cytokine release and inflammatory cell death in monocyte-derived 
macrophages from CF patients versus healthy controls.
10,84
  Inflammatory cytokine release 
by CF murine and human macrophages stimulated with LPS was increased versus wild type 
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and healthy controls.
13
  In a murine CF model of A. fumigatus infection, Ianitti et al observed 
increased activation of the NLRP3 inflammasome in CF lung macrophages versus wild type 
controls.
19
 
 
CFTR-defective T-cells  
The role of T cells in immunity to pulmonary aspergillosis is well recognised with Th1, Th2, 
Th17, Th9 and cyt toxic T cells all playing a role.
85-87
 Th1 CD4+ T cells enable inflammation 
and fungal clearance, whilst Th17 cells are important for neutrophil recruitment, Th2 cells 
for allergic inflammation and Th9 responses play a role in fibrosis. Furthermore, a role for T 
regulatory (Treg) cells has been described in regulation of innate and adaptive responses.
88
  
CF lymphocyte unresponsiveness to bacterial pathogens has been long established 
89
, with a 
tendency for a pro-allergic Th2 response and increased tendency to develop allergic 
Aspergillus lung disease in patients with CF.
23,90
 This is consistent with CF murine models 
where A. fumigatus challenge leads to a shift to IgE, IL-4 and IL-13 production.
91
 
Furthermore, T helper cells from CF patients have lower levels of interferon-ɣ production 
and increased IL-10 production.
92
 It has been hypothesized that this is a consequence of 
increased calcium flux across the T cell membrane.
93
 Calcium flux has been shown to be 
regulated by CFTR, and is crucial for T cell activation. Murine studies have specifically 
demonstrated that T cell receptor stimulation led to increased calcium entry in CFTR-
deficient T cells, and increased translocation of the calcineurin-dependent transcription 
factor NFAT.
94
 Thus, excessive calcium flux as a direct consequence of CFTR dysfunction in T 
cells may be a major contributor to dysregulated immune responses in CF.  
Recent studies showed that CFTR
-/- 
mice have increased innate lymphoid cell IL-9 production 
in response to A. fumigatus challenge, which is linked to expansion of Th9 T cells.
87
 IL-9 
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neutralisation led to an improvement in lung immunopathology and fibrosis. Further studies 
in the murine model of pulmonary aspergillosis showed that CFTR dysfunction led to 
defective indoleamine 2,3-dioxygenase activity, leading to alterations in tryptophan 
metabolism with a subsequent imbalance of the Th17/Treg axis and excessive lung 
inflammation.
18
 Therapeutic modulation of this pathway to enhance indoleamine 2,3-
dioxygenase enabled resolution of excessive inflammation.
18
 Clinical studies have also 
shown that the co-stimulatory molecule, OX40 ligand, is critical for driving CD4+ Th2 
responses in CF patients with ABPA.
95
 This correlated with low vitamin D levels in serum. 
Notably ex vivo therapy with vitamin D led to reduced OX40 ligand expression and reduced 
Th2 responses.
95
 These studies indicate that a better understanding of the hyper-
inflammatory T cell responses in CF may open up new immunotherapeutic avenues for the 
treatment of fungal-driven lung disease. 
 
Summary and Future Directions 
Aspergillus colonisation is commonly observed in patients with CF, with A. fumigatus most 
frequently encountered, and can manifest in clinically recognized CF-related Aspergillus 
diseases as ABPA and fungal sensitization. Persistent Aspergillus colonisation or Aspergillus 
bronchitis are not well defined and should receive more attention. Only incomplete data 
exists with respect to A. fumigatus colonisation dynamics and time of acquisition. In 
addition, the impact of persistent Aspergillus colonisation (infection) on lung function 
decline in CF has not been studied sufficiently. A systematic approach in which standardized 
fungal diagnostic measurements are applied in a longitudinal way to a large cohort of 
patients with CF, is urgently needed to assess the impact of persistent Aspergillus 
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colonisation. The findings of such investigations will inform clinical decision making with 
respect to the need of therapeutic interventions.  
Treatment of persistent Aspergillus colonisation in the absence or presence of clinical 
symptoms of pulmonary exacerbation and/or a decline in lung function with antifungals has 
not been properly assessed. The only study which aimed to target persistent Aspergillus 
infection in patients with CF was flawed by largely underdetectable serum itraconazole 
concentrations.
96
 Well-known adverse effects of long term azole antifungal therapies, 
including the rapid emerging triazole antifungal resistance, toxicity and interaction with 
CFTR modulators, will challenge the use of azole antifungals for persistent Aspergillus 
colonisation and infection. 
Enhanced mechanistic insights in the impairments in innate antifungal immune mechanisms 
is warranted to identify new targets for non-allergic Aspergillus infections in CF patients. 
Currently, the observed Aspergillus-induced inflammatory responses by innate immune cells 
in both in vitro, ex vivo and experimental models of infection, seem to be a potential target 
to limit the pathological consequences of CF-related Aspergillus infection.  A range of anti-
inflammatories are being developed for the general treatment of CF-related airway 
disease.
97
 It will be crucial to understand the impact both on reducing hyper-inflammatory 
responses as well as whether there is an effect on direct antifungal killing mechanisms. The 
CFTR modulators are the first causative treatment options for CF patients and have achieved 
significant improvement in lung function and quality of life.
98
 One study showed a clear 
reduction in fungal colonisation in the CF lung - an effect that may be associated with the 
mitigation of the impaired innate immune mechanisms observed in CF immune cells.
50
 In 
vitro work, which showed that a defective CFTR is associated with impaired degranulation of 
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antimicrobial proteins in neutrophils, has demonstrated that ivacaftor is able to correct 
degranulation and to increase bacterial killing by activation of Rab27a.
75
 Another example of 
a small molecule based therapy targeting both the primary defect in CF as well as the 
aberrant inflammation and immune response, is thymosin α1. Thymosin α1 is a natural 
occurring polypeptide, used as an immunomodulator in viral infections, malignancies and 
immunodeficiencies, and has recently been shown to increase CFTR maturation and to 
reduce inflammation in preclinical models of disease.
99
 Its mode of action seems to be the 
induction of IDO1 which in turns induces autophagy and favourable influencing the balance 
of protein folding versus degradation of the CFTR.
99
 
There is considerable interest in immunotherapeutic approaches to the treatment of fungal 
disease.
100
 Recombinant cytokines have been used extensively in transplant-related fungal 
disease
100
, and recently successful use of interferon-gamma in CF-related fungal disease was 
reported.
101
 Targeting the increased inflammasome activation and IL-1β release with the IL-
1-receptor antagonist Anakinra, has shown promising results in pre-clinical models of 
disease.
19
 Improved understanding of Aspergillus disease pathogenesis in CF patients will 
lead to new therapeutic targets and should eventually result in new management options. 
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Table 1. Overview of studies reporting Aspergillus colonisation rates in patients with cystic fibrosis. 
References 
 
Focus Country Patient population 
Duration and 
frequency of 
sampling* 
Colonisation rates 
Nelson, 1979 [22] primary USA 46 pts once 56.7% Asp colonisation 
(no info if ABPA or sens) 
Laufer, 1984 [23]  primary USA 100 pts aged 2 – 34 yrs once 9% Af colonisation overall  
10% in those with ABPA 
Bauernfeind, 
1987 [24] 
secondary Germany 102 pts 22 mo period, multiple 
samples 
5.9% Af colonisation 
(no info if ABPA or sens) 
Mroueh, 1994 [25] primary USA 236 pts aged 1 – 41 yrs 
(mean age 14.5 yrs) 
retrospective 25.4% overall Af colonisation 
19% isolated Af colonisation 
6.5% Af colonisation + ABPA  
based on single cultures 
Flume, 1994 [26] primary USA 27 pts prior to lung 
transplantation  
once 63% Asp colonisation  
(no info if ABPA or sens) 
Cimon, J Med 
Mycol 1995 [in 27] 
primary France 210 pts once 21.4% Af pos culture 
(only 1% ABPA in the study population) 
Becker, 1996 [28]  primary USA 49 adult pts 1 yr cross-sectional  16% Af colonisation 
(no data if ABPA or sens) 
based on single cultures 
Milla, 1996 [29]  primary USA 212 paediatric pts > 5 yrs 
mean age 17.2 +/- 9.2 yrs 
multiple 
1 yr study period  
21.2% at least one Asp pos culture  
 
Burns, 1998 [30] secondary USA 465 pts > 6 yrs once 23.2% Asp colonisation 
(ABPA or sens not exclusion criteria for 
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study) 
Burns, 1999 [31] secondary USA 520 pts ≥ 6 yrs of age, FEV1 
25%-75% predicted 
twice  
(baseline and end of 
study) 
25% Asp colonisation baseline 
16.2% wk 20 (end of study) 
(18% vs 8%, tobra vs placebo) 
Bargon, 1999 [32] 
primary Germany 104 adult pts repeated cultures 41.3% Asp colonisation 
(no info if ABPA or sens)  
Cimon, 2000 [33]  secondary France   128 pts (98 adults and 30 
paediatric pts) 
longitudinal, 5 yrs, 
minimum 4 samples/pt 
46.1% at least one Af pos culture  
(only 4% ABPA in the population 
studied) 
Hodson, 2002 [34] secondary UK/Ireland 42 (tobramycin) + 37 
(colistin) pts ≥ 6 yrs 
once at end of study 5.7% Af pos in tobramycin group 
3.2% Af pos in colistin group 
Bakare, 2003 [35] primary Germany  94 pts, median age 28 yrs  multiple, 6 mo study 
period 
45.7% Af colonisation 
24.5% had ≥ 2 Af positive cultures 
(no info if ABPA or sens) 
Skov, 2005 [36] primary Australia 270 paediatric and adult 
pts 
2 samples/yr 
4 yr study period  
Increase from 7.4% to 18.8%  
(based on single Af pos cultures) 
ABPA 0.3 to 4% 
Chotirmall, 2008 
[37] 
primary  Irish 50 pts during exacerbations 
5 yrs study period 
30% at least one Asp positive culture 
20%  > 1 Asp pos culture 
4% ≥ 10 Asp pos culture 
12% ABPA 
Valenza, 2008 [38]  primary Germany  60 adult and paediatric pts 
[median 18 yrs, 6 -41 yrs] 
multiple samples 
1 yr study period 
58.3% A. fumigatus pos 
10% non-fumigatus Aspergillus pos  
(based on single positive cultures) 
Paugam, 2010 [39] primary France 201 adult pts multiple samples 
2 yrs study period 
56.7% in total study population 
 (based on one Af pos culture) 
28% age group 6-10 yrs 
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59% age group 11-15 yrs 
75% age group 16-20 yrs 
61% age group 21-41 yrs 
Nagano, 2010 [40] secondary Ireland 77 adult pts, median 28.5 
yrs [18-59 yrs] 
once 9.1% all Asp species 
5.2% A. fumigatus 
(no info ABPA or sens) 
Jubin, 2010 [41] primary France 85 paediatric pts 
mean age 8.5 +/- 9 yrs  
 
 
multiple 
at least once/yr 
6 yrs study period 
21% Asp colonisation 
14% isolated persistent Asp 
colonisation  
4% Asp colonisation + ABPA 
Sudfeld, 2010 [42] primary US 614 pts 10 yr study period, 
cohort 
36.3% A. fumigatus (single pos culture) 
26.1% non-fumigatus Aspergillus 
De Vrankrijker, 
2011 [43] 
primary Netherlands 259 pts non-ABPA 
106 pts 0-12 yrs 
99 pts 13-24 yrs 
54 pts ≥25 yrs  
multiple in one yr 23.6% (>50% of cultures Af pos) 
16.4% age group 0-12 yrs 
54.1% age group 13-24 yrs 
29.5% age group ≥ 25 yrs 
Wainwright, 2011 
[44] 
secondary Australia 153 pts, BAL fluid from 
children < 5 yrs 
during pulmonary 
exacerbations 
9% Asp colonisation/infection 
Fillaux, 2012 [45] primary France 206 pts 
median age 16.3 yrs 
[range 9.8-23.6] 
routine samples, 
median follow-up 3.6 
yrs [range 2.1–8.7] 
 
18% persistent carriage = 3 Af pos 
cultures in 6 mo 
 (non-ABPA or sens)  
62.1% at least one Af pos culture 
27.1% persistent carriage period at 
least once 
Güngör, 2013 [46] primary Turkey 48 pts, mean age 11.6 yrs 
[range 2-38 yrs] 
at least 3 sputum/deep 
throat swab samples 
10.4% one A. fumigatus pos culture 
8.3% non-fumigatus Aspergillus 
(no info ABPA or sens) 
Page 32 of 33
http://mc.manuscriptcentral.com/tmmy
Medical Mycology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Fillaux 2014 [47] primary France 117 paediatric pts 
median age 9.9 yrs [IQR 
6.0-13.2] at end of study 
routine 
8 yrs period 
38.5% (= 3 Af pos cultures in 6 mo) 
without sensitization 
Masoud-Landgraf, 
2014 [48] 
secondary Austria 113 pts, median 20.3 yrs 
[range 2-57] 
multiple samples 
1 yr study period 
78.8% Af pos cultures  
(no info ABPA or sens) 
Noni, 2015 [49] primary Greece 121 paediatric pts routine 32.2% one Af pos culture 
11.6% chronic colonisation 
Ramsey, 2014 [6] primary Australia 56 infants ≤ 2yrs of age 3 BAL samples 
 2 yrs study period 
12.5% Asp colonisation  
Heltshe, 2015 [50] secondary USA 151 pts: 
38 pts 6-11 yrs 
32 pts 12-17 yrs 
81 pts ≥18 yrs 
3 cultures as per study 
protocol 
~15% and ~7.5% Asp pos cultures 
before and after ivacaftor 
(no info ABPA or sens) 
Saunders, 2016 
[51] 
primary UK 45 children < 18 yrs of 
age 
multiple 29% Af pos BAL culture 
14% Af pos sputum 
42% one Af pos culture 
22% persistent colonisation 
Mirkovic, 2016 
[52] 
primary Ireland 48 pts 8 sputum samples 
2 year period 
60.9% in Af sens pts 
24% in non-sens pts (at least one pos) 
Gernez, 2016 [53] primary US & 
Ireland 
48 and 26 adult pts At least 2 pos sputum 
cultures within previous 
2 yrs 
US 27.1% Af pos  
Ireland 30.8% Af pos  
Reece, 2017 [54] primary Ireland CF registry 
749 pts 
median 18.1 yrs [range 4-
retrospective,  
1 yr study period 
11% overall Af colonisation 
(5% persistent and 6% intermittent)  
ABPA 5.9%
#
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69] ≤ 10 yrs of age: 0 – 10%  
11-20 yrs of age: 10-30%  
21-30 yrs: 7-18%  
≥31 yrs: 0-18% 
Brandt, 2018 [55] primary Germany  CF Registry 
2599 pts  
(mean age 21 yrs +/- 
12yrs) 
1 yr study period 32.5% at least one Af pos culture/yr  
(no info if ABPA or sens) 
Hong, 2018 [56] primary US  CF Foundation registry 
16,095 pts (6 -45 yrs) 
Retrospect 
6 yrs study period 
at least 2 cultures/yr, 
Asp prevalent cases 
excluded 
27.9% Asp pos overall 
9.6% persistent Asp pos (≥2 pos  
cultures during 12 mo; of which 5.4% 
ABPA)  
18.4% transient of which 3.4% ABPA 
Coron, 2018 [57] primary France 243 pts > 6 yrs  
(mean age 21.2 +/- 8.7 
yrs) 
prospective, samples 
annually or during 
exacerbation 
3 yr study period 
35.4% one Af pos culture 
adults 35.6%  
children 34.8%  
*based on sputum samples unless indicated otherwise; #patients intermittently or persistently colonised with A. fumigatus showed no increased 
prevalence of ABPA; Af, Aspergillus fumigatus; Asp, Aspergillus species; ABPA, allergic bronchopulmonary aspergillosis; sens, fungal sensitisation; pos, 
positive; 
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